
Nuwellis
Founded Year
1999Stage
IPO - II | IPOTotal Raised
$32.3MAbout Nuwellis
Nuwellis is an early-stage medical device company focused on commercializing the Aquadex FlexFlow System. The company's commercial product, the Aquadex system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. The company was formerly known as CHF Solutions and changed its name to Nuwellis. The company was founded in 1999 and is based in Eden Prairie, Minnesota.
Missing: Nuwellis's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Nuwellis's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Nuwellis
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Nuwellis is included in 1 Expert Collection, including Medical Devices.
Medical Devices
3,501 items
https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.
Nuwellis Patents
Nuwellis has filed 41 patents.
The 3 most popular patent topics include:
- Fluid dynamics
- Angiology
- Blood

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
3/26/2020 | 8/23/2022 | Blood tests, Blood, Hematology, Fluid dynamics, Cardiovascular physiology | Grant |
Application Date | 3/26/2020 |
---|---|
Grant Date | 8/23/2022 |
Title | |
Related Topics | Blood tests, Blood, Hematology, Fluid dynamics, Cardiovascular physiology |
Status | Grant |
Latest Nuwellis News
Jan 10, 2023
Major Wall Street indices closed mixed on Monday with the Nasdaq Composite being the only one to end the session on a positive note, led by gains in technology shares. The Dow Jones and the S&P 500 ended in the red. read more
Nuwellis Frequently Asked Questions (FAQ)
When was Nuwellis founded?
Nuwellis was founded in 1999.
Where is Nuwellis's headquarters?
Nuwellis's headquarters is located at 12988 Valley View Road, Eden Prairie.
What is Nuwellis's latest funding round?
Nuwellis's latest funding round is IPO - II.
How much did Nuwellis raise?
Nuwellis raised a total of $32.3M.
Who are the investors of Nuwellis?
Investors of Nuwellis include Gambro, Investor Growth Capital, Brightstone Venture Capital, MPM Capital, Mason Wells and 6 more.
Who are Nuwellis's competitors?
Competitors of Nuwellis include Brain Tunnelgenix Technologies, SynCardia Systems, Sensible Medical Innovations, GlySure, Drew Scientific and 10 more.
Compare Nuwellis to Competitors
IntelliDx, Inc. is a development stage medical device company focused on the commercialization of an automated blood glucose monitoring device.
Nephrologix Inc. is a private company that develops, manufactures and markets peritoneal dialysis (PD) systems.
Vytrace Corporation is developing a new critical care monitor to monitor glucose at the bedside of critically ill patients in the Intensive Care Unit. The product is designed specifically for patients in the ICU. Vytrace Corporation is developing a new critical care monitor to monitor glucose at the bedside of critically ill patients in the Intensive Care Unit. The product is designed specifically for patients in the ICU. This is not a consumer product for diabetic glucose monitoring. They also are exploring other analytes that may be monitored with their sensor technology. Vytrace Corporation has a highly accurate bedside monitor that automatically and continuously monitors blood glucose via a fiberoptic catheter with a photonic crystal sensor on the tip.
Sensible Medical Innovation develops a sensing and monitoring technology that provides actionable and accurate data for guiding the management and treatment of several chronic medical conditions.
Spineworks Medical, Inc. designs and manufactures medical devices for spinal surgery.
Atritech has developed the WATCHMAN, an implantable device designed to capture clots that may form in the left atrial appendage of patients with atrial fibrillation, thereby aiming to reduce the risk of stroke and eliminating the need for long-term use of blood thinning medications.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.